The Wall Street Journal has an article about using genomics to develop vaccines -- something that Novartis in particular has been developing. A vaccine for a certain form of meningitis, for instance, is showing promise in clinical trials and "Novartis plans to move [it] into a much-larger test involving thousands of children next year, says Rino Rappuoli, an Italian scientist who heads Novartis's vaccine research," according to the article.